Chester County News and Community Website
BALA CYNWYD, PA — Larimar Therapeutics, Inc. has begun a rolling application for accelerated U.S. approval of its experimental Friedreich’s ataxia treatment, positioning the biotechnology company to potentially launch the …
Larimar Starts FDA Filing for FA Drug With Mid-2027 Goal Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) plans to begin a rolling FDA biologics license application submission next month for its experimental Friedreich’s ataxia treatment nomlabofusp as the …
Larimar Targets FDA Filing for Friedreich’s Ataxia Drug Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) said it recently published data supporting the use of skin-based frataxin measurements as a surrogate endpoint for its experimental therapy nomlabofusp, …
Larimar Data Support Surrogate Endpoint for Nomlabofusp Approval Path Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported fourth-quarter and full-year 2025 financial results while advancing its lead candidate nomlabofusp toward a planned FDA filing for the treatment …
Larimar Reports Results, Advances Nomlabofusp Toward FDA Filing Read More BALA CYNWYD, PA — Larimar Therapeutics Inc. (Nasdaq: LRMR) said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to nomlabofusp for the treatment of adults and children …
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) said members of its management team will present and hold one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference …
Larimar Heads to JPMorgan as Rare Disease Program Draws Investor Attention Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced third-quarter 2025 financial results and a clinical update highlighting continued progress in its nomlabofusp development program for Friedreich’s ataxia (FA), …
Larimar Reports Promising Friedreich’s Ataxia Data as Nomlabofusp Nears Phase 3 Launch Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported new long-term open-label (OL) data for nomlabofusp in Friedreich’s ataxia (FA), showing sustained increases in frataxin (FXN) protein and consistent …
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported second-quarter 2025 results, highlighting progress toward a planned Biologics License Application (BLA) for nomlabofusp, a potential first disease-modifying therapy for …
Larimar Therapeutics Advances Nomlabofusp Program Toward 2026 FDA Filing Read More BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the publication of two new peer-reviewed articles detailing nonclinical data supporting the therapeutic potential of its investigational frataxin replacement …
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data Read More